Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the company opened ...
Researchers Present Ozempic Alternatives—Without Sickening GI Side Effects
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...
Crain's New York20h
FiDi-based obesity drug maker sees $1.9B IPO
Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.
Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...
The Healthy on MSN22h
6 Foods To Eat on Semaglutides, Listed by a Doctor of Obesity Medicine
A triple-board-certified MD of lifestyle and obesity medicine lists the foods that will optimize your medication's efficacy and minimize unwanted side effects.